

- Assembling existing data and information from manufacturers and processors of existing chemical nanoscale materials.
- Encouraging the development of test data needed to provide a firmer scientific foundation for future work and regulatory/policy decisions.
- Identifying and encouraging use of a basic set of risk management practices in developing and commercializing nanoscale materials.

The concept paper outlines proposed ideas for reporting on nanoscale materials in commerce, developing data on representative nanoscale materials, and identifying risk management practices. It describes who may wish to participate, the reporting expectations for participants, what the program could entail and what EPA intends to do with the data generated from the program. It also describes the potential benefits of participation.

EPA will use the data from NMSP to gain an understanding of which nanoscale materials are produced, in what quantities, how they are used, and the data that is available for such materials. EPA scientists will use data collected through this program, where appropriate, to aid in determining how and whether certain nanoscale materials or categories of nanoscale materials may present risks to human health and the environment.

This release of the two draft documents for public review and comment are an important part of the collaborative development process for NMSP. These draft documents are intended to further discussion about NMSP and will serve as the foundation for establishing the details of NMSP.

The Agency also intends to conduct a public meeting to obtain further public comment on these documents and any other issues pertaining to a NMSP and will announce that meeting date in a separate **Federal Register** notice. EPA will consider all comments and announce the availability in the **Federal Register** of the final versions of the ICR, TSCA Inventory paper and a document that describes NMSP. Once the details of NMSP have been announced, EPA will implement NMSP.

III. Request for Comments

While EPA is seeking comment on all aspects of NMSP and the TSCA Inventory paper, the Agency is especially interested in comments on the following items:

1. Whether the data elements that have been identified in NMSP are appropriate for nanoscale materials.
2. Timing and phasing of submissions under the NMSP basic and in-depth

programs and whether approaches for tiering data submissions are appropriate.

3. Who would participate in NMSP and how to encourage participation, especially from small and medium sized enterprises.

4. What criteria to use for NMSP program evaluation and views on the timing and nature of any reports the Agency may issue.

5. How to engage industry and other stakeholders in the NMSP in-depth program and approaches for generating test data.

6. The processes and roles for EPA, participants, and other stakeholders during development and evaluation of data for the in-depth program.

7. Possible approaches for identification and use of alternative sources of data, in order to minimize the burden of information collection associated with NMSP.

8. Uses for the data submitted to EPA under the NMSP program.

9. Issues relevant to scope, definitions, and descriptions.

10. The suitability of the approach for determining the TSCA Inventory status of nanoscale materials discussed in the TSCA Inventory paper referenced in Unit II.C.

11. Whether, in combination, the TSCA Inventory paper and the NMSP concept paper are sufficiently clear in how EPA plans at this time to address nanoscale materials that are new or existing chemicals under TSCA and the NMSP and, if needed, an indication of areas where further clarification may be warranted.

IV. Summary of Next Steps

As indicated previously, EPA intends to use a collaborative process that involves stakeholders in the design, development, and implementation of NMSP. In addition to providing comments on the draft documents released by this document, EPA invites you to participate in the process. If you would like EPA to notify you as the stewardship program moves forward, please sign-up at <http://www.epa.gov/oppt/nano/nano-contact.htm>.

EPA will announce the date and logistics of a public meeting on NMSP in a separate **Federal Register** notice and the TSCA nanotechnology website <http://www.epa.gov/oppt/nano>.

Following consideration of all comments received on this notice, EPA will announce availability in the **Federal Register** of the final versions of the ICR, TSCA Inventory paper, and a document that describes NMSP. Once the details of the NMSP have been

developed and announced, EPA will implement NMSP.

List of Subjects

Environmental protection, Chemicals, Hazardous substances, Nanoscale materials.

Dated: July 9, 2007.

James Jones,

Acting Assistant Administrator, Office of Prevention, Pesticides and Toxic Substances.

[FR Doc. E7-13558 Filed 7-11-07; 8:45 am]

BILLING CODE 6560-50-S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. E7-13143) published on pages 37223-37224 of the issue for Monday, July 9, 2007.

Under the Federal Reserve Bank of Chicago heading, the entry for Fenton Financial, Inc., Fenton, Michigan, is revised to read as follows:

A. Federal Reserve Bank of Chicago
(Burl Thornton, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. *Fentura Financial, Inc.*, Fenton, Michigan; to acquire 24.9 percent of the voting shares of Premier Commercial Bank, Arizona, National Association, Mesa, Arizona.

Comments on this application must be received by July 31, 2007.

Board of Governors of the Federal Reserve System, July 9, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7-13529 Filed 7-11-07; 8:45 am]

BILLING CODE 6210-01-S

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. E7-13180) published on page 37224 of the issue for Monday, July 9, 2007.

Under the Federal Reserve Bank of Boston heading, the entry for Royal Bank of Scotland Group, plc, the Royal Bank of Scotland, plc, RBSG International Holdings Limited, all of Edinburgh, Scotland, Citizens Financial Group, Providence, Rhode Island, Banco Santander Central Hispano, S.A., Madrid, Spain, Santander Holanda B.V., Delft, Netherlands, Fortis N.V., Utrecht, Netherlands, Fortis S.A./N.V., Fortis Brussels, S.A./N.V., Fortis Bank S.A./

N.V., all of Brussels, Belgium, Fortis Bank Nederland (Holding) N.V., Utrecht, Netherlands, and RFS Holdings B.V., Amsterdam, Netherlands, is revised to read as follows:

A. Federal Reserve Bank of Boston
(Richard Walker, Community Affairs Officer) P.O. Box 55882, Boston, Massachusetts 02106-2204:

1. *Royal Bank of Scotland Group, plc, Edinburgh, Scotland, Banco Santander Central Hispano, S.A., Madrid, Spain, Santander Holanda B.V., Delft, Netherlands, Fortis N.V., Utrecht, Netherlands, Fortis S.A./N.V., Fortis Brussels, S.A./N.V., Fortis Bank, all of Brussels, Belgium, Fortis Bank Nederland (Holding) N.V., Utrecht, Netherlands, and RFS Holdings B.V., Amsterdam, Netherlands;* to control ABN AMRO Holding N.V. Amsterdam, Netherlands, and thereby indirectly acquire ABN AMRO North American Holding Company, LaSalle Bank Corporation, LaSalle Bank National Association, all of Chicago, Illinois, and LaSalle Bank Midwest National Association, Troy, Michigan. In connection with this proposal Fortis Bank Nederland (Holding) N.V., Santander Holland B.V. and RFS Holdings B.V. have applied to become bank holding companies.

In addition, each of The Royal Bank of Scotland Group, plc, The Royal Bank of Scotland plc, RBSG International Holdings Limited, all of Edinburgh, Scotland, and Citizens Financial Group, Inc., Providence, Rhode Island, has applied to acquire control of ABN AMRO North American Holding Company, LaSalle Bank Corporation, LaSalle Bank National Association, and LaSalle Bank Midwest National Association in a transfer subsequent to the acquisition of control of ABN AMRO Holding N.V.

Comments on this application must be received by July 25, 2007.

Board of Governors of the Federal Reserve System, July 9, 2007.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. E7-13530 Filed 7-11-07; 8:45 am]

BILLING CODE 6210-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Ethics Subcommittee, Advisory Committee to the Director (ACD), Centers for Disease Control and Prevention (CDC)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), CDC announces the following meeting for the aforementioned subcommittee.

Times and dates: 1 p.m.–5:30 p.m., August 9, 2007. 8:30 a.m.–3:30 p.m., August 10, 2007.

Place: CDC, 1825 Century Center, Conference Room 1 A/B, Atlanta, GA 30345.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people. To accommodate public participation in the meeting, a conference telephone line will be available. The public is welcome to participate during the public comment periods by calling (866) 919-3560 and entering code 4168828. The public comment periods are tentatively scheduled from 4:45 p.m.–5 p.m. on August 9, 2007 and from 3 p.m.–3:15 p.m. on August 10, 2007.

Purpose: The Ethics Subcommittee will provide counsel to the ACD, CDC regarding a broad range of public health ethics questions and issues arising from programs, scientists, and practitioners.

Matters To Be Discussed: Agenda items will include: Ethical Guidance for Public Health Emergency Preparedness and Response, Ethical Issues relating to CDC Partnerships, Public Health Ethics and Genomics, Ethical Guidance for Non-Research Data Collections, and Updates on Ethical Issues relating to Pandemic Influenza Preparedness. Agenda items are subject to change as priorities dictate.

For security reasons, members of the public interested in attending the meeting should contact the person below. The deadline for notification of attendance is August 2, 2007.

Contact Person for More Information: Drue Barrett, Ph.D., Designated Federal Official, Ethics Subcommittee, CDC, 1600 Clifton Road, NE., M/S D-50, Atlanta, Georgia 30333. Telephone (404) 639-4690. E-mail: d Barrett@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: July 5, 2007.

Elaine L. Baker,

Acting Director, Management Analysis and Services Office Centers for Disease Control and Prevention (CDC).

[FR Doc. E7-13523 Filed 7-11-07; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Antiviral Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public.

Name of Committee: Antiviral Drugs Advisory Committee.

General Function of the Committee:

To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on September 5, 2007, from 8 a.m. to 4 p.m. and on September 6, 2007, from 9 a.m. to 1 p.m.

Location: On September 5, 2007, the committee will meet at the Hilton Washington DC/Silver Spring, The Ballrooms, 8727 Colesville Rd., Silver Spring, MD. The hotel telephone number is 301-589-5200. On September 6, 2007, the committee will meet in closed session at FDA, White Oak Headquarters, rm. 2046, 10903 New Hampshire Ave., Silver Spring, MD.

Contact Person: Cicely Reese, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail:

Cicely.Reese@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512531. Please call the Information Line for up-to-date information on this meeting. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency's Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Agenda: On September 5, 2007, the committee will discuss new drug application (NDA) 22-145, raltegravir potassium, integrase inhibitor 400 milligram tablets, Merck & Co., Inc., for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection in combination with other